InvestorsHub Logo
Followers 0
Posts 7710
Boards Moderated 0
Alias Born 05/05/2020

Re: None

Thursday, 01/13/2022 10:42:36 AM

Thursday, January 13, 2022 10:42:36 AM

Post# of 13741
$QNTA announced that the Company’s venom-to-drug project was presented during an international conference organized by the Dominican Republic (“DR”) Ministry of Environment (“MOE”) for projects that utilize natural resources. The conference focused on projects that seek to use natural resources to improve the lives of humans, such as Medolife’s product, Escozine, which is registered as an alternative oncological medicine in the DR, and anticipates seeking approval as a COVID 19 treatment in both the United States, under PIND #150335, and the DR. The peptides obtained from the scorpion venom are used by the Company in combination with their patented polarization technology to create an ever-growing line of drugs and nutraceuticals.

The event was hosted by Vice Minister of Economic and Social Analysis of the DR Ministry of Economy, Planning and Development Alexis Cruz; Vice Minister of Protected Areas and Biodiversity of the DR Ministry of Environment Federico Franco; and Ambassador of the Federal Republic of Germany in the DR Volker Pellet. Other notable attendees at the conference included Director of International Cooperation of the Ministry of National Planning and Economic Policy Saskia Rodríguez, together with Vice Minister of the Environment of the Ministry of Environment and Energy of Costa Rica Franklin Paniagua.

The first day of the conference was held in Santo Domingo, which is the capital of the DR, while on the second day the international committee visited Medolife’s scorpion reservation in the Neyba province, which houses Rhopalurus princeps scorpions endemic to the region, commonly referred to as “blue scorpions”. The visiting committee observed and noted the high level of training for workers at the reservation, the diligent care for the scorpions, and the positive effects it has for the region’s locals. Medolife is also committed to hire and train more female employees in 2022. CEO of Medolife Dr. Arthur Mikaelian led discussions on the Company’s projects with various representatives of the international committee during the conference.

“Some members of the conference expressed interest in presenting our project to their respective countries,” said Dr. Mikaelian. “We had a productive conversation with the German ambassador, who would like to present Escozine as a COVID-19 treatment to interested institutions in the German government, with plans to reconnect beginning of 2022 to explore this opportunity. In addition, there was interest in the polarization technology and its capabilities. We are pleased with the reception we received and the outcome of these presentations. We believe the combination of natural resources and technology will be the start of a new generation of drugs and nutraceuticals, which are capable of improving the lives of people - and we believe this conference proves that the venom-to-drug concept is gaining international recognition.”
https://marketwirenews.com/news-releases/medolife-rx-presents-its-venom-to-drug-development-p-6781854054062201.html

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.